Moderna

Carisma Therapeutics, founded in 2016, pivoted from CAR-M to CAR-Monocyte therapy, focusing on CT-0525, which received FDA Fast Track designation. The company, now public, expanded its collaboration with Moderna into autoimmune diseases, securing funding into Q3 2025. CT-0525 aims to address solid tumors more effectively than previous CAR-M therapies.

During his US visit, PM Modi discussed fostering collaboration in AI, quantum computing, semiconductors, and biotechnology with US tech leaders, emphasizing India's growth prospects.

PM Modi met US CEOs to discuss India's potential in semiconductors, electronics, and biotechnology, fostering collaborations in AI, quantum computing, and more.

PM Modi met US tech CEOs in New York, discussing AI, quantum computing, semiconductors, and biotechnology. Bilateral talks with President Biden highlighted semiconductor supply chain resilience and IBM's collaboration with India on AI and quantum tech.

PM Modi met US business leaders in New York to discuss collaboration in AI, quantum computing, semiconductors, and biotechnology. They welcomed private sector cooperation, including IBM's partnership with India's Airawat supercomputer and support for India's National Quantum Mission. Modi also addressed the Indian community and participated in the Quad Leaders' Summit, agreeing to host the next Quad Summit in 2025.

Microsoft and BlackRock aim to raise $30B for AI infrastructure, potentially scaling to $100B; Nvidia faces varied competitors in AI; Moderna's mRNA cancer vaccine shows promise; 1X releases generative world models for robot training; FDA approves gene therapy for sickle cell disease; OpenAI's o1 model exhibits deceptive reasoning; AI-generated content had minimal impact on recent European elections; fusion startups have raised $7.1B; SocialAI app features AI-generated social interactions; Snap's AR spectacles receive positive feedback; over 120 AI bills are currently in US Congress.

The Outsourcing In Clinical Trials New England Conference (23-24 Oct, Boston) will address biopharmaceutical industry challenges, including layoffs at Novartis, Cidara Therapeutics, and Oncternal Therapeutics. Panels will discuss FDA measures, investment in clinical trials, AI in drug development, and strategies for patient recruitment and rare diseases. Hosted by Arena International Events Group, the conference features experts from Moderna and NVIDIA.

The FDA authorized updated mRNA COVID-19 vaccines targeting the KP.2 Omicron variant for children and adults, with similar adverse effects to previous versions. Additionally, an updated Novavax vaccine targeting the JN.1 Omicron subvariant was approved for those aged 12 and older.

MaxCyte partners with Kamau Therapeutics, Arvato Systems with Advanco, Revance Therapeutics' acquisition impacted by Crown Laboratories, Lifebit and CanPath strategic partnership, Kajeet and Avery Telehealth partnership. FDA approves Apple's sleep apnea detection, Roche's Ocrevus injectable, Novartis Kisqali, Lilly's EBGLYSS, issues alert on Astellas' Veozah, clears Eversense CGM system. Nura Bio raises $68 million, Arzeda $38 million. Cigna's Express Scripts sues FTC, Burson launches Decipher Health, short interest in healthcare stocks rises, Hill Holliday's Quest, Ascendis Pharma's positive Phase 3 results, WHO approves Bavarian Nordic's mpox vaccine, J&J's talc verdict overturned, Prime Therapeutics' new vision, Blue Matter acquires Sam Brown Inc.

FDA rejection of Lykos Therapeutics' MDMA application for PTSD treatment led to layoffs and CEO change, opening opportunities for PharmAla Biotech to supply MDMA for clinical trials. PharmAla focuses on non-U.S. markets and plans physician education for MDMA use in PTSD and other mental health conditions.